{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,5]],"date-time":"2026-09-05T11:51:11Z","timestamp":1788609071209,"version":"build-2803163510"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2022,1,1]],"date-time":"2022-01-01T00:00:00Z","timestamp":1640995200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2022,11,16]],"date-time":"2022-11-16T00:00:00Z","timestamp":1668556800000},"content-version":"vor","delay-in-days":319,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"DOI":"10.13039\/501100013161","name":"Swiss Life Stiftung f\u00fcr Chancenreichtum und Zukunft","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100013161","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Translational Autoimmunity"],"published-print":{"date-parts":[[2022]]},"DOI":"10.1016\/j.jtauto.2022.100172","type":"journal-article","created":{"date-parts":[[2022,11,19]],"date-time":"2022-11-19T18:41:58Z","timestamp":1668883318000},"page":"100172","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":13,"special_numbering":"C","title":["Mycophenolate mofetil as second line treatment in autoimmune hepatitis \u2013 A retrospective single center analysis"],"prefix":"10.1016","volume":"5","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-5027-3432","authenticated-orcid":false,"given":"Mirjam","family":"Kolev","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5889-7063","authenticated-orcid":false,"given":"Stefan","family":"Diem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Diem","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susana G.","family":"Rodrigues","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annalisa","family":"Berzigotti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3447-264X","authenticated-orcid":false,"given":"Guido","family":"Stirnimann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2707-765X","authenticated-orcid":false,"given":"Nasser","family":"Semmo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"6","key":"10.1016\/j.jtauto.2022.100172_bib1","doi-asserted-by":"crossref","first-page":"1496","DOI":"10.1016\/j.jhep.2020.07.023","article-title":"Second-line and third-line therapy for autoimmune hepatitis: a position statement from the European reference network on hepatological diseases and the international autoimmune hepatitis group","volume":"73","author":"Lohse","year":"2020","journal-title":"J. Hepatol."},{"issue":"4","key":"10.1016\/j.jtauto.2022.100172_bib2","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1016\/j.jhep.2021.12.041","article-title":"Systematic review of response criteria and endpoints in autoimmune hepatitis by the International Autoimmune Hepatitis Group","volume":"76","author":"Pape","year":"2022","journal-title":"J. Hepatol."},{"issue":"5","key":"10.1016\/j.jtauto.2022.100172_bib3","doi-asserted-by":"crossref","first-page":"820","DOI":"10.1016\/S0016-5085(19)33223-8","article-title":"Clinical, biochemical, and histological remission of severe chronic active liver disease: a controlled study of treatments and early prognosis","volume":"63","author":"Soloway","year":"1972","journal-title":"Gastroenterology"},{"issue":"158","key":"10.1016\/j.jtauto.2022.100172_bib4","doi-asserted-by":"crossref","first-page":"159","DOI":"10.1093\/oxfordjournals.qjmed.a067264","article-title":"Controlled prospective trial of corticosteroid therapy in active chronic hepatitis","volume":"40","author":"Cook","year":"1971","journal-title":"Q. J. Med."},{"issue":"7806","key":"10.1016\/j.jtauto.2022.100172_bib5","doi-asserted-by":"crossref","first-page":"735","DOI":"10.1016\/S0140-6736(73)92125-9","article-title":"Controlled trial of prednisone and azathioprine in active chronic hepatitis","volume":"1","author":"Murray-Lyon","year":"1973","journal-title":"Lancet"},{"issue":"11","key":"10.1016\/j.jtauto.2022.100172_bib6","doi-asserted-by":"crossref","first-page":"876","DOI":"10.1136\/gut.16.11.876","article-title":"Prednisone for chronic active liver disease: dose titration, standard dose, and combination with azathioprine compared","volume":"16","author":"Summerskill","year":"1975","journal-title":"Gut"},{"issue":"1","key":"10.1016\/j.jtauto.2022.100172_bib7","doi-asserted-by":"crossref","first-page":"191","DOI":"10.1016\/j.jhep.2010.01.037","article-title":"Treatment options for autoimmune hepatitis: a systematic review of randomized controlled trials","volume":"53","author":"Lamers","year":"2010","journal-title":"J. Hepatol."},{"issue":"3","key":"10.1016\/j.jtauto.2022.100172_bib8","doi-asserted-by":"crossref","first-page":"269","DOI":"10.1586\/egh.09.15","article-title":"Current and future treatments of autoimmune hepatitis","volume":"3","author":"Czaja","year":"2009","journal-title":"Expet Rev. Gastroenterol. Hepatol."},{"issue":"4","key":"10.1016\/j.jtauto.2022.100172_bib9","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1111\/j.1478-3231.2005.01141.x","article-title":"Autoimmune hepatitis type 1: safety and efficacy of prolonged medical therapy","volume":"25","author":"Seela","year":"2005","journal-title":"Liver Int."},{"issue":"5","key":"10.1016\/j.jtauto.2022.100172_bib10","doi-asserted-by":"crossref","first-page":"442","DOI":"10.1053\/jlts.2001.23356","article-title":"A randomized double-blind comparative study of mycophenolate mofetil and azathioprine in combination with cyclosporine and corticosteroids in primary liver transplant recipients","volume":"7","author":"Wiesner","year":"2001","journal-title":"Liver Transplant."},{"issue":"Suppl 1","key":"10.1016\/j.jtauto.2022.100172_bib11","doi-asserted-by":"crossref","first-page":"s2","DOI":"10.1177\/096120330501400102","article-title":"Mechanisms of action of mycophenolate mofetil","volume":"14","author":"Allison","year":"2005","journal-title":"Lupus"},{"key":"10.1016\/j.jtauto.2022.100172_bib12","series-title":"Immunologie Grundlagen und Wirkstoffe","first-page":"455","author":"Vollmar Angelika","year":"2005"},{"key":"10.1016\/j.jtauto.2022.100172_bib13","article-title":"Successful treatment of therapy-refractory autoimmune hepatitis with mycophenolate mofetil","volume":"28","author":"Schuppan","year":"1998","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.jtauto.2022.100172_bib14","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.jhep.2010.12.032","article-title":"Mycophenolate for the treatment of autoimmune hepatitis: prospective assessment of its efficacy and safety for induction and maintenance of remission in a large cohort of treatment-naive patients","volume":"55","author":"Zachou","year":"2011","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.jtauto.2022.100172_bib15","doi-asserted-by":"crossref","first-page":"1950","DOI":"10.1016\/j.cgh.2017.06.001","article-title":"Efficacy and safety of mycophenolate mofetil and tacrolimus as second-line therapy for patients with autoimmune hepatitis","volume":"15","author":"Efe","year":"2017","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"2","key":"10.1016\/j.jtauto.2022.100172_bib16","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/j.dld.2018.10.004","article-title":"Mycophenolate mofetil treatment in patients with autoimmune hepatitis failing standard therapy with prednisolone and azathioprine","volume":"51","author":"Giannakopoulos","year":"2019","journal-title":"Dig. Liver Dis."},{"issue":"3","key":"10.1016\/j.jtauto.2022.100172_bib17","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1016\/j.jceh.2014.05.003","article-title":"Role of mycophenolate mofetil for the treatment of autoimmune hepatitis-an observational study","volume":"4","author":"Jothimani","year":"2014","journal-title":"J Clin Exp Hepatol"},{"issue":"3","key":"10.1016\/j.jtauto.2022.100172_bib18","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1111\/j.1365-2036.2011.04727.x","article-title":"The role of mycophenolate mofetil in the management of autoimmune hepatitis and overlap syndromes","volume":"34","author":"Baven-Pronk","year":"2011","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"10","key":"10.1016\/j.jtauto.2022.100172_bib19","doi-asserted-by":"crossref","first-page":"588","DOI":"10.1155\/2010\/891252","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory or intolerant to conventional therapy","volume":"24","author":"Sharzehi","year":"2010","journal-title":"Can. J. Gastroenterol."},{"issue":"2","key":"10.1016\/j.jtauto.2022.100172_bib20","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1016\/j.cgh.2017.09.063","article-title":"Efficacy and safety of mycophenolate mofetil in patients with autoimmune hepatitis and suboptimal outcomes after standard therapy","volume":"16","author":"Roberts","year":"2018","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"5","key":"10.1016\/j.jtauto.2022.100172_bib21","doi-asserted-by":"crossref","first-page":"321","DOI":"10.1155\/2004\/504591","article-title":"Mycophenolate mofetil for the treatment of autoimmune hepatitis in patients refractory to standard therapy","volume":"18","author":"Devlin","year":"2004","journal-title":"Can. J. Gastroenterol."},{"issue":"5","key":"10.1016\/j.jtauto.2022.100172_bib22","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/apt.13907","article-title":"Expert clinical management of autoimmune hepatitis in the real world","volume":"45","author":"Liberal","year":"2017","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"1","key":"10.1016\/j.jtauto.2022.100172_bib23","doi-asserted-by":"crossref","first-page":"169","DOI":"10.1002\/hep.22322","article-title":"Simplified criteria for the diagnosis of autoimmune hepatitis","volume":"48","author":"Hennes","year":"2008","journal-title":"Hepatology"},{"issue":"2","key":"10.1016\/j.jtauto.2022.100172_bib24","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1002\/hep.510240201","article-title":"An algorithm for the grading of activity in chronic hepatitis C. The METAVIR Cooperative Study Group","volume":"24","author":"Bedossa","year":"1996","journal-title":"Hepatology"},{"issue":"4","key":"10.1016\/j.jtauto.2022.100172_bib25","doi-asserted-by":"crossref","first-page":"971","DOI":"10.1016\/j.jhep.2015.06.030","article-title":"European association for the study of the L. EASL clinical practice guidelines: autoimmune hepatitis","volume":"63","year":"2015","journal-title":"J. Hepatol."},{"issue":"12","key":"10.1016\/j.jtauto.2022.100172_bib26","doi-asserted-by":"crossref","first-page":"3063","DOI":"10.1111\/j.1572-0241.2008.02180.x","article-title":"Mycophenolate mofetil as second line therapy in autoimmune hepatitis?","volume":"103","author":"Hennes","year":"2008","journal-title":"Am. J. Gastroenterol."},{"issue":"9","key":"10.1016\/j.jtauto.2022.100172_bib27","doi-asserted-by":"crossref","first-page":"1036","DOI":"10.1016\/j.cgh.2008.04.006","article-title":"A single center review of the use of mycophenolate mofetil in the treatment of autoimmune hepatitis","volume":"6","author":"Hlivko","year":"2008","journal-title":"Clin. Gastroenterol. Hepatol."},{"issue":"10","key":"10.1016\/j.jtauto.2022.100172_bib28","doi-asserted-by":"crossref","first-page":"1120","DOI":"10.1111\/apt.15528","article-title":"Adverse events related to low dose corticosteroids in autoimmune hepatitis","volume":"50","author":"van den Brand","year":"2019","journal-title":"Aliment. Pharmacol. Ther."},{"issue":"4","key":"10.1016\/j.jtauto.2022.100172_bib29","doi-asserted-by":"crossref","first-page":"461","DOI":"10.1002\/acr.24130","article-title":"American college of rheumatology guideline for the management of reproductive health in rheumatic and musculoskeletal diseases","volume":"72","author":"Sammaritano","year":"2020","journal-title":"Arthritis Care Res."},{"issue":"1","key":"10.1016\/j.jtauto.2022.100172_bib30","doi-asserted-by":"crossref","first-page":"8","DOI":"10.1016\/j.jhep.2009.03.011","article-title":"Mycophenolate mofetil to the rescue in autoimmune hepatitis: a fresh sprout on the decision tree","volume":"51","author":"Czaja","year":"2009","journal-title":"J. Hepatol."},{"key":"10.1016\/j.jtauto.2022.100172_bib31","article-title":"First results from a propensity matching trial of mycophenolate mofetil vs. Azathioprine in treatment-naive AIH patients","volume":"12","author":"Dalekos","year":"2021","journal-title":"Front. Immunol."},{"key":"10.1016\/j.jtauto.2022.100172_bib32","article-title":"Long-term results of mycophenolate mofetil vs. azathioprine use in patients with autoimmune hepatitis","author":"Dalekos Gn","year":"2022","journal-title":"J HEP reports"},{"issue":"5","key":"10.1016\/j.jtauto.2022.100172_bib33","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1136\/gut.50.5.713","article-title":"Characteristics of autoimmune hepatitis in patients who are not of European Caucasoid ethnic origin","volume":"50","author":"Zolfino","year":"2002","journal-title":"Gut"},{"issue":"4","key":"10.1016\/j.jtauto.2022.100172_bib34","doi-asserted-by":"crossref","first-page":"998","DOI":"10.1002\/hep.1840180435","article-title":"Meeting report: international autoimmune hepatitis group","volume":"18","author":"Johnson","year":"1993","journal-title":"Hepatology"},{"issue":"11","key":"10.1016\/j.jtauto.2022.100172_bib35","doi-asserted-by":"crossref","first-page":"2519","DOI":"10.1007\/s10620-008-0632-0","article-title":"Mycophenolate mofetil for autoimmune hepatitis: a single practice experience","volume":"54","author":"Wolf","year":"2009","journal-title":"Dig. Dis. Sci."},{"issue":"9","key":"10.1016\/j.jtauto.2022.100172_bib36","doi-asserted-by":"crossref","first-page":"819","DOI":"10.1097\/01.mcg.0000177260.72692.e8","article-title":"Empiric therapy of autoimmune hepatitis with mycophenolate mofetil: comparison with conventional treatment for refractory disease","volume":"39","author":"Czaja","year":"2005","journal-title":"J. Clin. Gastroenterol."},{"issue":"4","key":"10.1016\/j.jtauto.2022.100172_bib37","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1111\/j.1478-3231.2005.01107.x","article-title":"Transplant immunosuppressive agents in non-transplant chronic autoimmune hepatitis: the Canadian association for the study of liver (CASL) experience with mycophenolate mofetil and tacrolimus","volume":"25","author":"Chatur","year":"2005","journal-title":"Liver Int."}],"container-title":["Journal of Translational Autoimmunity"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909022000338?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S2589909022000338?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,11,11]],"date-time":"2025-11-11T23:34:29Z","timestamp":1762904069000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S2589909022000338"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022]]},"references-count":37,"alternative-id":["S2589909022000338"],"URL":"https:\/\/doi.org\/10.1016\/j.jtauto.2022.100172","relation":{},"ISSN":["2589-9090"],"issn-type":[{"value":"2589-9090","type":"print"}],"subject":[],"published":{"date-parts":[[2022]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Mycophenolate mofetil as second line treatment in autoimmune hepatitis \u2013 A retrospective single center analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Translational Autoimmunity","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jtauto.2022.100172","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2022 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"100172"}}